Public Sector Pension Investment Board Invests $6.62 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)

Public Sector Pension Investment Board bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 283,000 shares of the biopharmaceutical company's stock, valued at approximately $6,619,000. Public Sector Pension Investment Board owned approximately 0.18% of TG Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in TGTX. Lazard Asset Management LLC acquired a new stake in TG Therapeutics during the 1st quarter worth $91,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of TG Therapeutics by 6.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 85,603 shares of the biopharmaceutical company's stock valued at $1,303,000 after purchasing an additional 5,015 shares during the last quarter. Cetera Advisors LLC acquired a new stake in shares of TG Therapeutics in the 1st quarter valued at about $622,000. DekaBank Deutsche Girozentrale acquired a new position in TG Therapeutics during the first quarter worth approximately $58,000. Finally, Assenagon Asset Management S.A. purchased a new stake in TG Therapeutics in the second quarter valued at approximately $8,698,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on TGTX shares. B. Riley raised their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. raised their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. TD Cowen started coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price for the company. Finally, HC Wainwright boosted their price target on TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX traded down $0.20 during midday trading on Friday, hitting $34.80. The stock had a trading volume of 1,262,171 shares, compared to its average volume of 4,315,347. TG Therapeutics, Inc. has a 1 year low of $12.37 and a 1 year high of $36.84. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a 50 day moving average price of $26.59 and a two-hundred day moving average price of $22.29. The company has a market capitalization of $5.42 billion, a PE ratio of -347.97 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business's revenue for the quarter was down 49.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.73 EPS. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 10.50% of the stock is currently owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.